Clinical Trials Logo

Clinical Trial Summary

The Phase I/II study will be conducted as an open label, multiple center study of CS-7017, an experimental drug and paclitaxel chemotherapy in subjects with advanced anaplastic thyroid cancer. Biopsies will be obtained from patients with accessible tumor at baseline, two-weeks after the first CS-7017 dosage (prior to the start of combination therapy) and at the end of the first study cycle (week 3 of combination therapy), in order to evaluate the effects of the study drug alone and in combination with the chemotherapy agent on the tumor. Treatment will continue until disease progression or the development of intolerable toxicities.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT00603941
Study type Interventional
Source Daiichi Sankyo, Inc.
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date January 2008
Completion date December 2011

See also
  Status Clinical Trial Phase
Recruiting NCT04420754 - Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer Phase 1
Completed NCT02152137 - Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer Phase 2
Active, not recruiting NCT04552769 - Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer Phase 2
Active, not recruiting NCT04400474 - Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study Phase 2
Completed NCT02688608 - Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Phase 2
Terminated NCT00095693 - Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer Phase 2
Active, not recruiting NCT01240590 - A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) Phase 1/Phase 2
Not yet recruiting NCT05819593 - Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences
Active, not recruiting NCT04579757 - Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06374602 - Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer Phase 2
Recruiting NCT06362694 - Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy Phase 2
Withdrawn NCT01701349 - Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer Phase 3
Active, not recruiting NCT03085056 - Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer Early Phase 1
Recruiting NCT01774279 - interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)
Terminated NCT00126568 - Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer Phase 2
Completed NCT02244463 - A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer Phase 1/Phase 2
Active, not recruiting NCT05696548 - Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) Phase 2
Completed NCT00280852 - Review of Multimodality Management of Anaplastic Thyroid Cancer N/A
Recruiting NCT04238624 - Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer Phase 2
Recruiting NCT06079333 - NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) Phase 2